| Date | Title | | | May 01, 2013 | MiMedx Announces Record First Quarter 2013 Results |  | | Apr 22, 2013 | MiMedx Group, Inc. Announces Listing on the NASDAQ Capital Market| MiMedx Common Stock to begin trading on NASDAQ under the symbol "MDXG" on April 25, 2013
KENNESAW, Ga., April 22, 2013 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its common stock has been approved for listing on The NASDAQ Capital Market under the ticker symbol "MDXG." Trading on NASDAQ is expected to commence on ... |
| | | Apr 16, 2013 | MiMedx Group, Inc. Announces Release Date for 2013 First Quarter Results| KENNESAW, Ga., April 16, 2013 /PRNewswire/ -- MiMedx Group, Inc. (OTC: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its results for the first quarter ended March 31, 2013, will be released before the opening of the market on Wednesday, May 1, 2013. MiMedx will host a live broadcast of its first quarter conference call on Wednesday, May 1, 2013 at 10:30 AM EDT. A... |
| | | Apr 11, 2013 | MiMedx to Present at Regen Med Investor Day 2013| KENNESAW, Ga., April 11, 2013 /PRNewswire/ -- MiMedx Group, Inc. (OTC: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the 1st Annual Regen Med Investor Day in New York. Michael J. Senken, Chief Financial Officer and Donald B. Ayers, Vice President, National Strategic Accounts, are scheduled to present on April 17th at 5:00 p.m. EDT at the Harmo... |
| | | Mar 18, 2013 | MiMedx Responds To Inquiries Regarding Trading Activity; Reiterates First Quarter And Full Year Goals|
KENNESAW, Ga., March 18, 2013 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that MiMedx management has received a number of inquiries regarding trading activity in its shares late last week and the resultant drop in the trading price for the Company's common stock.
After investigation, management believes that on Thurs... |
| | | Mar 14, 2013 | MiMedx to Present at the Canaccord Genuity Musculoskeletal Conference| KENNESAW, Georgia, March 13, 2013 (PR Newswire) – MiMedx Group, Inc. (OTC: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the Canaccord Genuity Musculoskeletal Conference in Chicago. Parker H. “Pete” Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present on March 19... |
| | | Mar 07, 2013 | MiMedx Announces 2012 Results | | | Feb 11, 2013 | MiMedx is Issued Four Additional U.S. Patents for Placental Tissue Grafts| PRESS RELEASE Contact: Michael Senken
Phone: (678) 384-6720
MIMEDX IS ISSUED FOUR ADDITIONAL U.S. PATENTS FOR PLACENTAL TISSUE GRAFTS
KENNESAW, Georgia, February 11, 2013 (PR Newswire) -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its receipt of four new issued patents related to tissue grafts derived from the placenta. The U.S. Patent... |
| | | Feb 07, 2013 | MiMedx Group, Inc. Announces Release Date for 2012 Fourth Quarter Results| PRESS RELEASE Contact: Michael Senken
Phone: (678) 384-6720
MiMedx Group, Inc. Announces Release Date for 2012 Fourth Quarter Results
KENNESAW, Georgia, February 7, 2013 (PR Newswire) – MiMedx Group, Inc. (OTC: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its results for the fourth quarter ended December 31, 2012, will be released before the opening of the ma... |
| |
|
